CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 90 enrolled
Drug / intervention
Combination of pimecrolimus and fluticasone +1 moredrug
Likely dose
Pimecrolimus cream twice daily and fluticasone cream 0.05% once dailyAI-extracted
Key inclusion· 5
  • Age 2 to 65 years
  • Clinical diagnosis of atopic dermatitis per AAD Consensus Conference (2001)
  • At least two bilateral symmetric severe AD lesions with m-EASI ≥7, erythema ≥3, and papulation/infiltration ≥3 on each site, differing by ≤2 points between sides
  • Willingness and ability to comply with study requirements
Key exclusion· 7
  • History of immune deficiencies or malignant disease
  • Moderate to severe lichenification at target areas (score 2 or 3)
  • Active cutaneous bacterial, viral, or fungal infections in target areas
  • History of other skin disorders (e.g., Netherton syndrome) that could interfere with evaluations

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00119158
NCT00119158Phase 4Completed

An Exploratory Double-blind, Randomized, Vehicle-controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Elidel Cream 1% and Cutivate Cream 0.05% in Patients With Severe Lesions of Atopic Dermatitis (AD)

Children's Hospital of Philadelphia·interventional·Posted Jul 13, 2005·Updated Jul 27, 2010

In Brief

A Phase 4 clinical trial evaluating Combination of pimecrolimus and fluticasone and pimecrolimus for Atopic Dermatitis. Completed, enrolled 90 participants across 3 sites.

Detailed Summary

Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 13, 2005
Enrollment StartOct 1, 2004
Primary CompletionJun 1, 2005
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 21.0 years ago

Interventions

Combination of pimecrolimus and fluticasonedrug

Pimecrolimus cream twice a day and fluticasone cream once a day

pimecrolimusdrug

apply daily with fluticasone cream for flares